2
Jan
2019

From Merck Fast Track to Computer Chem Frontier: Karen Akinsanya on The Long Run

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

A Single Shot for Heart Disease: Sekar Kathiresan on The Long Run
Gene Editing for Transplants and Cell Therapy: Luhan Yang on The Long Run
Creative New Treatments for Mental Health: Steve Paul on The Long Run
Seeking Impact: Servier’s David Lee on The Long Run Podcast